Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Liabilities and Shareholders Equity (2017 - 2025)

Historic Liabilities and Shareholders Equity for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to $577.4 million.

  • Dianthus Therapeutics' Liabilities and Shareholders Equity rose 6300.59% to $577.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 2653.82%. This contributed to the annual value of $374.0 million for FY2024, which is 10847.13% up from last year.
  • Dianthus Therapeutics' Liabilities and Shareholders Equity amounted to $577.4 million in Q3 2025, which was up 6300.59% from $326.1 million recorded in Q2 2025.
  • In the past 5 years, Dianthus Therapeutics' Liabilities and Shareholders Equity ranged from a high of $577.4 million in Q3 2025 and a low of $78.6 million during Q2 2023
  • For the 4-year period, Dianthus Therapeutics' Liabilities and Shareholders Equity averaged around $258.8 million, with its median value being $194.4 million (2022).
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first tumbled by 5707.44% in 2023, then skyrocketed by 36918.67% in 2024.
  • Quarter analysis of 4 years shows Dianthus Therapeutics' Liabilities and Shareholders Equity stood at $83.1 million in 2022, then surged by 115.86% to $179.4 million in 2023, then skyrocketed by 108.47% to $374.0 million in 2024, then surged by 54.39% to $577.4 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $577.4 million for Q3 2025, versus $326.1 million for Q2 2025 and $348.6 million for Q1 2025.